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changed between the two time periods. Also, the use of PBSC
instead of BMSC increased (P0.0001). In order to evaluate the
relative importance of these factors a multivariate analysis will be
performed. Conclusion: The pronounced improvement in TRM
during recent years seem to be multi factorial however, an im-
proved donor selection strategy is probably the main cause.
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IMPROVEMENT OF MATCHED SIBLING DONOR ENGRAFTMENT WITH
SIROLIMUS ADDED TO A NON-MYELOABLATIVE CONDITIONING REG-
IMEN
Claxton, D.F.; Ehmann, C.; Shaffer, M.; Rybka, W. Penn State College
of Medicine, Hershey, PA.
Non-myeloablative regimens extend the beneﬁt of allogeneic
hematopoietic transplantation to many otherwise ineligible pa-
tients. Anti-tumor effects are however thought not to occur for
most patients until full donor chimerism is achieved. We have
recently added sirolimus to an established conditioning regimen in
an attempt to optimize engraftment and anti-tumor effects while
minimizing morbid GVHD. We compare results of two sequential
studies conditioning patients with hematological malignancies with
cyclophosphamide (days 7 and 6) and ﬂudarabine (days 7
through 3) prior to matched sibling peripheral blood stem cell
transplantation. All received tacrolimus and methotrexate immu-
noprophylaxis. 9 patients were enrolled in the initial study, and 6/9
also received Campath 1H 20 mg IV on day 7 of the regimen.
The second study has treated 10 patients with sirolimus added to
the immunosuppression and adjusted to 5–15 ng/ml beginning on
day7 (no Campath was given on this study). Tacrolimus has been
tapered off in this protocol between days 30–45, but sirolimus has
continued. Graft versus host disease occurred prior to day 100 in
5/9 patients on protocol 1 and 2/10 patients on protocol 2. In all
cases GVHD was controllable and no patient has died of transplant
related causes. In both protocols all patients showed some degree
of donor engraftment by RFLP or XY FISH analysis by day 30.
Mean fractional peripheral blood donor chimerism values through
day 180 are given in the table below. There is no signiﬁcant
interaction between treatment and time (p-value0.8579), hence
the engraftment curves for the two protocols are parallel. Based on
a repeated measures analysis using general F-statistics, there is a
signiﬁcant treatment effect, with patients on the second protocol
showing an average of 18% higher engraftment (p-value0.0281).
While follow-up is shorter for patients on Protocol 2, 8/10 patients
are beyond 180 days from transplant and the other two have both
achieved 0.98 fractional donor engraftment. We conclude that
our second protocol, using sirolimus with early tapering of tacroli-
mus, appears to yield more rapid and complete donor chimerism
(Table).
Donor Fractional Whole Blood Chimerism
Day 15 Day 30 Day 100 Day 180
Protocol 1 0.51 0.75 0.82 0.81
Protocol 2 with Sirolimus 0.72 0.88 0.99 1.00
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IMATINIB ONLY FOR MOLECULAR RELAPSE IS NOT SUFFICIENT TO
ACHIEVE A DURABLE COMPLETE CHIMERIC STATUS AND MOLECULAR
REMISSION AFTER ALLO HCT IN CML
Soydan, E.; Civriz, S.; Beksac, M.; Koc, H.; Gurman, G.; Ilhan, O.;
Arat, M Ankara University Medical School Department of Hematology,
Ankara, Turkey.
Background: Allogeneic hematopoietic cell transplantation (Al-
loHCT); today, is still the only treatment modality that provides
cure for CML. But relapses after AlloHCT are still an ongoing
problem. In most of these patients donor lymphocyte infusions
(DLI) are effective to achieve molecular remission (MR). Post DLI
aplasia and GVHD are the most important reasons of morbidity
and mortality in these patients. Imatinib is a tyrosine kinase inhib-
itor and blocks CML progenitor cell proliferation. The effect of
imatinib on relapse after AlloHCT has been investigated in a few
studies including patients with chronic and accelerated phase
CML. In this study we aimed to analyze the effect of imatinib on
post AlloHCT molecular relapse. Patients and Method: Imatinib
was applied 400 mg/day p.o. at least for six months to 11 patients;
transplanted from their HLA identical siblings with molecular
relapse. Patients were monitored closely with ATM Multiplex
PCR for chimerism and RQ-PCR (LightCycler, Roche Diagnos-
tics) for bcr-abl/G6PDH. Results: Eleven of the patients were
under imatinib treatment for more than 6 months. Seven of the 11
patients responded to imatinib. At the end of the sixth month
except two patients all of them had donor type chimerism. Peri-
orbital edema developed in 4 of the patients, and none of the
patients had Gr 3–4 GIS and hematologic side effect. After cessa-
tion of the drug ﬁve patients had durable MR and complete
chimeric (CC) status. Two patients with second molecular relapse
and mix chimeric status after imatinib, and four patients with
primary imatinib resistance received DLI. After median 12 (6–20)
months follow up, imatinib sensitive 5 patients were in continuing
MR, imatinib sensitive two patients with second relapse were in
MR and CC after DLI. One of the imatinib refractory patients was
lost after DLI induced acute GVHD in MR, The remaining
patients did not achieve MR. One patient is still receiving DLI,
IFN and imatinib. Conclusion: Imatinib treatment for molecular
relapse after AlloHCT has acceptable adverse event proﬁle and
provides over 60% MR rate but this response was not durable as in
DLI; 25% of the patients experience second relapse early after
cessation of the drug. DLI may achieve MR in 50% of the primary
imatinib resistant patients. Concerning the in vitro effect if ima-
tinib on T cell functions there is an urgent need for prospective
studies comparing DLI and imatinib	DLI with close follow up of
chimerism.
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CAN WE CONSIDER FLUDARABINE/ FULL DOSE I.V. BUSULFAN A RE-
DUCED INTENSITY CONDITIONING REGIMEN?
Chunduri, S.; Jessop, E.; Dobogai, L.; Peace, D.; Saunthararajah, Y.;
Chen, Y.-H.; Mahmud, N.; Maynard, V.; Hoffman, R.; Rondelli, D.
University of Illinois at Chicago, Chicago, IL.
In this study we analyzed 22 patients who received an allogeneic
HSCT from matched related (n17) or unrelated (n5) donors,
and were conditioned with FLU/BU (ﬂudarabine 30 mg/m2/d  4
days followed by single dose i.v. busulfan 3.2 mg/kg/d  4 days)
(n12) or with the FLU/MEL (ﬂudarabine 30 mg/m2/d  5 days
and melphalan 70 mg/m2/d  2 days) (n10) RIC regimen. Me-
dian age was 26 yrs (range: 19–51) in the FLU/BU group and 47
yrs (range: 22–57) in the FLU/MEL group (p0.02). High risk
patients were 8/12 in the FLU/BU group (7 AML in relapse, 1
CML-AP) and 3/10 in the FLU/MEL group (2 resistant NHL and
1 HD). GVHD prophylaxis was FK-506/MTX and in 9/12
FLU/BU cases (including 5 MUD) Thymoglobulin was added. All
FLU/MEL and 6/12 FLU/BU patients received PBSC (median nr.
CD34 cells: 5.0 and 5.9 106/kg, respectively), while 6 FLU/BU
received marrow cells (median nr. CD34 cells: 1.58  106/kg).
Median time to ANC 500 was comparable in PBSC FLU/BU
(d14, range: 11–20), and PBSC FLU/MEL (d12, range: 10–15)
patients, while it was longer in bone marrow FLU/BU (d 22, range:
17–37) patients (p 0.01 and p0.001, respectively). Time to Plt
20K was d 12 (range: 10–16) in the PBSC FLU/MEL group and
d 20 (range: 17–37) in the bone marrow FLU/BUS group. Four of
6 PBSC FLU/BU patients did not have severe thrombocytopenia
(
20K) after transplant. Mucositis  grade 2 was never observed.
Median length of stay in the hospital after transplant was 17 days
(range: 13–37) in PBSC FLU/MEL, 23 days (range: 18–42) in
PBSC FLU/BU and 30 d (range: 22–38) in bone marrow FLU/
BU. Median chimerism levels on d30 after transplant were: 100%
in FLU/MEL and 95% (1 rejection) in FLU/BU. Median fol-
low-up for patients currently alive is 254 days (range: 145–628) in
the FLU/BU group and 636 days (range: 429–715) in the FLU/
MEL group. Acute GVHD grade II-IV was seen in 1 FLU/BU
patient after DLI and in 1 FLU/MEL patient. Chronic GVHD is
Poster Session I
25B B & M T
present in 2/6 FLU/BU and 4/9 FLU/MEL evaluable patients. Six
of 12 patients in the FLU/BU died of relapse (n4) and/or infec-
tion (n2, 1 within d100 ) and 3 of 10 patients in the FLU/MEL
died of relapse. In conclusion, since in allogeneic PBSC transplan-
tation the FLU/BU regimen seems to have a myelotoxicity com-
parable to FLU/MEL, it could be used in allotransplant for elderly
patients and may represent a platform for donor lymphocyte infu-
sions in high risk patients.
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ALEMTUZUMAB IMMUNOTHERAPY PROVIDES EFFECTIVE CYTORE-
DUCTION PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION FOR
REFRACTORY LYMPHOPROLIFERATIVE DISORDERS
Voralia, M.1,2; Hasegawa, W.1,2; McAllister, R.2; Evjen, A.2; Briggs,
S.2; Doell, H.2; Danyluk, P.2 1. University of Saskatchewan, Saskatoon,
SK, Canada; 2. Saskatchewan Cancer Agency, Saskatoon, SK, Canada.
Introduction: The optimal cytoreductive therapy for refractory
chronic lymphoproliferative disorders prior to allogeneic stem cell
transplantation is not well deﬁned. Immunotherapy may represent
an alternative cytoreductive strategy in chemotherapy refractory
disease. We assessed the role of alemtuzumab (anti-CD52, CAM-
PATH) immunotherapy in reducing disease bulk pretransplant in
a pilot single center clinical protocol. Patients and Methods:
Patients with CLL and lymphoplasmacytic lymphoma (LPL) re-
fractory to at least two prior lines of chemotherapy, age less than 65
years, and adequate organ function received alemtuzumab mono-
therapy 30 mg. intravenously thrice weekly for 8–12 weeks. Mo-
lecular, hematologic, and radiological responses were measured.
Transplantation conditioning consisted of Fludarabine/Melphalan
or BEAM. Results: Between 10/2002 and 10/2004, 7 patients (6
refractory CLL, 1 refractory LPL) received alemtuzumab cytore-
duction and allogeneic stem cell transplantation. All patients had
received prior ﬂudarabine or alkylator therapy; 1 had received
rituximab. High-risk cytogenetic markers (p53 or Rb1 deletions)
were present in 4 of 6 CLL patients, as assessed by FISH. Marrow
involvement decreased from a mean of 80% pre-alemtuzumab to
15% post; 3 patients attained complete marrow clearance. Hema-
tologic remission following alemtuzumab was achieved in 4 of 6
CLL patients. Partial (3/7) or complete (4/7) molecular remission
was achieved in all patients after immunotherapy. Four patients
exhibited partial radiologic responses; 3 were unchanged. Adverse
effects were rare (CMV viremia in 2 patients; moderate cytopenias
requiring brief therapy interruption in 4). All 7 patients proceeded
to allogeneic stem cell transplantation (4 MRD, 3 MUD), one in
clinical relapse. Neutrophil engraftment was rapid (less than 20
days); one patient had delayed platelet engraftment. Although early
to assess long-term disease response, 4/4 evaluable patients have
achieved a complete molecular, hematologic, and radiologic re-
sponse at 6 months post-transplant; one patient remains in com-
plete remission at 2 years. One patient died of sepsis at 3 months.
Conclusion: Alemtuzumab immunotherapy is an effective cytore-
ductive regimen for chemotherapy-refractory lymphoproliferative
disorders prior to allogeneic stem cell transplantation, and bears
testing in a larger multi-centre Phase II/III protocol.
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THE FREQUENCY OF EARLY COMPLICATIONS AFTER ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) WITH MYELOA-
BLATIVE (MA) AND NON-MYELOABLATIVE (NMA) CONDITIONING
REGIMEN
Golovchenko, R.A.; Moiseev, S.I. The Russian Institute of Hematology
and Transfusiology, St-Petersburg, Russian Federation.
The frequency of early complications (before 100 days) of HSCT
was measured on 38 patients (pts) with hemoblastosis, underwent
allogeneic HSCT (allo HSCT) from HLA-matched related donors
(median age 24.4 	 1.8). Conditioning regimens were myeloabla-
tive in 28 patients (73.7%, median age 21 	 2.0) and consist
BuCy, and NMA in 10 patients (26.3%, median age 29.9 	 3.6),
consist of FluBuALG or FluBuAlkeran. In group of MA
HSCT 13 patients had CML, 9 - ALL, 5 - AML and 1 - MDS. In
group of NMA HSCT 6 patients had CML, 2 - ALL, 1 - AML, 1
- MDS. The frequency of bacterial infectious complications in
NMA HSCT group was 21.4% and in MA HSCT group 20%
(p0.05). The frequency of febrile neutropenia was signiﬁcantly
lower in NMA HSCT group: 30% and 67,8% respectively
(p
0.05). Viral complications was observed in 14 (50%) patients in
group of MA HSCT and in 5 patients (50%) in NMA group. 8 pts
(28.6%) in MA group developed CMV viremia and 4 pts (40%) in
NMA group (p0.05). Herpes simplex infection was diagnosed in
6 pts (21.4%) in group of MA HSCT and in 1 pt (10%) in NMA
HSCT group (p0.05). Hemorrhagic complications were ob-
served in 14 patients with MA HSCT (50%) and in 4 (40%) with
NMA HSCT (p0.05). Acute graft versus host disease (GVHD)
grade 2–4 was observed in 5 patients with MA HSCT (17.8%) and
in 1 pt (10%) in group of NMA HSCT (p0.05) and chronic
GVHD was developed in 9 pts in MA HSCT group and in 1 pt in
NMA HSCT group (p0.05). The toxicity of conditioning regi-
mens (only grade 3–4 were considered) for cardiovascular system
was signiﬁcant lower for NMA HSCT group: 1 pt (10%) and 11
pts (39.2%), (p
0.05). The toxicity for digestive system was lower
in NMA HSCT group too: 5 pts (50%) and 28 (100%) respectively
(p
0.05). The for respiratory system (7.1% and 0% respectively,
p0.05), urogenital system (25% and 20% respectively, p0.05),
and hepar (46.3% and 40% respectively, p0.05) had no signiﬁ-
cant differences between two groups. 1 pt in group NMA HSCT
had veno-occlusive disease (10%) and no cases in group MA
HSCT (p0.05). The engraftment of stem cells was achieved in
100% cases as in MA as NMA HSCT groups (25.5 	 4.5 and
20.5 	 1.2 days respectively, p0.05). We conclude, that there are
no differences between patients groups with MA and NMA HSCT
in spite of engraftment kinetics, the frequency of infectious com-
plications, the frequency of acute and chronic GVHD. But the use
of NMA HSCT accompany note lower toxicity on cardiovascular
and digestive systems.
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UNRELATED CORD BLOOD TRANSPLANTATION WITH MYELOABLATIVE
CONDITIONING FOR ADULT PATIENTS WITH HEMATOLOGICAL MALIG-
NANCIES
Yamane, A.; Mori, T.; Aisa, Y.; Nakazato, T.; Yamazaki, R.; Ikeda, Y.;
Okamoto, S. Division of Hematology, Keio University School of Medi-
cine, Tokyo, Japan.
Background: Umbilical cord blood (CB) has been rapidly estab-
lished as an alternative source of stem cells to bone marrow or
peripheral blood for unrelated allogeneic hematopoietic stem cell
transplantation. However, concern about the engraftment failure
probably due to low number of stem cells has limited its use
particularly for adult patients. We report the results of unrelated
cord blood transplantation (CBT) for 8 adult patients with hema-
tological malignancies. Patients and Methods: Patients with he-
matological malignancies without a suitable related donor were
eligible. Conditioning consisted of total body irradiation (TBI; 120
cGy) followed by high-dose cytarabine (3 g/m2  8) for myeloid
malignancies, and TBI (120 cGy) followed by high-dose cytarabine
(2 g/m2  4) and cyclophosphamide (60 mg/kg  2) for lymphoid
malignancies. For acute graft-versus-host disease prophylaxis, ta-
crolimus (0.03 mg/kg) and short-term methotrexate (15 mg/m2on
day 1, 10 mg/m2on days 3, 6) were given. All patients received
G-CSF infusion starting on day 1 until neutrophil recovery was
obtained. Cord blood unit was selected according to the nucleated
cell number (more than 2.0  107/kg) and HLA compatibility (less
than serological 2-loci mismatches). Results: Eight patients were
enrolled. Median age was 39 years (range, 20–58), and median
number of cryopreserved nucleated cells in the CB unit was 2.9 
107/kg (range, 2.0–4.7  107/kg). Their diagnoses were AML in 3
(2nd CR, 2; primary induction failure (PIF), 1), Ph1 ALL (1st
CR) in 2, advanced MDS in 2, and CML (2nd CP) in 1. All patients
achieved engraftment with full donor chimerism. Acute GVHD
occurred in 5 patients, and the grading was grade I in 2 and grade
II in 3 patients. Chronic GVHD occurred only in 2 patients. No
transplant-related mortality was observed, and overall survival was
100% with a median follow-up 14.7 months (range, 6.1–33.8
months). One patient with AML (PIF) relapsed 13 months after
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